2E9 Stock Chart & Stats
€0.09
<€0.01(11.11%)
At close: 4:00 PM EDT
€0.09
<€0.01(11.11%)
Day’s Range― - ―
52-Week Range€0.01 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€39.89M
Enterprise Value€135.56
Total Cash (Recent Filing)€145.63M
Total Debt (Recent Filing)€357.00K
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 20, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)€1.60M
Bulls Say, Bears Say
Bulls Say
Low Leverage & Strong EquityIntervacc’s minimal debt and sizable equity base provide durable financial flexibility, lowering refinancing and interest risks. This capital cushion supports ongoing R&D and commercialization spending over the medium term and gives the company runway to execute partnerships or roll out Strangvac without immediate liquidity stress.
Commercialized Core ProductHaving a commercial vaccine (Strangvac) and distribution/commercial partners moves Intervacc beyond pure R&D-stage risk. Product sales in approved markets create a durable, operational revenue stream and a path to scale via partner channels, reducing binary regulatory risk tied solely to trials.
Improving Cash Generation TrendA ~48% improvement in free cash flow versus the prior period suggests operational and cash-efficiency gains. While still negative, this trend points to improving control over costs and working capital, which, if sustained, materially reduces the time to reach break-even cash generation.
Bears Say
Severe Cash BurnPersistent negative operating cash flow and large free cash outflows are structural constraints: absent a rapid revenue ramp or external financing, cash reserves will decline, forcing dilution, asset sales, or partner dependence. This limits strategic optionality over the medium term.
Negative Unit Economics And MarginsNegative gross profit and extreme operating losses show core product economics have not yet scaled to cover costs. That structural margin weakness must be corrected via pricing, cost reduction, or volume growth; otherwise the business model cannot sustainably generate shareholder value.
Negative Returns On EquityROE around -26% signals the company is eroding its equity capital through losses. Even with a large equity base today, sustained negative returns will deplete resources, reduce financial flexibility, and increase the likelihood of future recapitalization or strategic dilution.
Intervacc AB News
2E9 FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was €0.01 and its highest was €0.11 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is €39.89M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 18 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -€0.005 earnings per share for the quarter, the consensus estimate of -€0.005 by €0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is >-0.01.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -€0.005 in its last earnings report, expectations of -€0.005. Following the earnings report the stock price went down -6.494%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in DE:2E9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―